Our top pick for
Intec Pharma Ltd is a biotechnology business based in the US. Intec Pharma shares (NTEC) are listed on the NASDAQ and all prices are listed in US Dollars. Intec Pharma employs 38 staff and has a market cap (total outstanding shares value) of USD$19.3 million.
|52-week range||USD$2.2 - USD$11.2|
|50-day moving average||USD$4.8612|
|200-day moving average||USD$4.711|
|Wall St. target price||USD$9|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.276|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-28.25%|
|Return on equity TTM||-96.24%|
|Market capitalisation||USD$19.3 million|
TTM: trailing 12 months
There are currently 511,124 Intec Pharma shares held short by investors – that's known as Intec Pharma's "short interest". This figure is 4.2% up from 490,548 last month.
There are a few different ways that this level of interest in shorting Intec Pharma shares can be evaluated.
Intec Pharma's "short interest ratio" (SIR) is the quantity of Intec Pharma shares currently shorted divided by the average quantity of Intec Pharma shares traded daily (recently around 719892.95774648). Intec Pharma's SIR currently stands at 0.71. In other words for every 100,000 Intec Pharma shares traded daily on the market, roughly 710 shares are currently held short.
However Intec Pharma's short interest can also be evaluated against the total number of Intec Pharma shares, or, against the total number of tradable Intec Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intec Pharma's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Intec Pharma shares in existence, roughly 130 shares are currently held short) or 0.1302% of the tradable shares (for every 100,000 tradable Intec Pharma shares, roughly 130 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Intec Pharma.
Find out more about how you can short Intec Pharma stock.
We're not expecting Intec Pharma to pay a dividend over the next 12 months.
Intec Pharma's shares were split on a 1:20 basis on 30 October 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Intec Pharma shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Intec Pharma shares which in turn could have impacted Intec Pharma's share price.
Over the last 12 months, Intec Pharma's shares have ranged in value from as little as $2.2 up to $11.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intec Pharma's is 1.2065. This would suggest that Intec Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program; and a feasibility agreement with GW Research Limited to explore an undisclosed research program using the Accordion Pill platform. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.